S&P 500 Healthcare Sector SEC Filings — September 11, 2026

EVP of Manufacturing and Supply Chain sold 48 shares total ($17.1K) under a 10b5-1 plan at avg $356.73; stock trades at $365.79 — near all-time highs. Plan selling suggests pre-scheduled portfolio rebalancing, not negative conviction.

CVP TAVR Lippis exercised 619 options at $72.68 and sold at $87.51, banking ~$9.2K profit per transaction. With TAVR market share concerns lingering, this ~20% realized gain and share reduction (1.5% of holdings) is a minor bearish signal on near-term valuation.

CMO Berger Dietmar had 263 shares withheld for taxes ($38.1K) after exercising 533 RSUs — a routine tax-withholding event (not a discretionary sale). Post-transaction holdings of 19,522 shares indicate strong alignment.

EVP, General Counsel Cain Wettan Keeley had 285 shares withheld for taxes ($41.3K) after exercising 590 RSUs. Similar to CMO pattern — no directional signal, but insider retains ~93% of exercised shares.

EVP of Global Quality Seymour Melissa gifted 29 shares total (17+12) — a low-materiality event (<0.5% of holdings for typical executive). Gifting to family/trust suggests tax planning, not bearish outlook.

CVP Chopra Daveen had 398 shares withheld for taxes ($34.5K) — no open-market selling. With 43,926 post-transaction holdings, this reflects minimal insider cash-out.

Three Form 4 filings (unparseable EDGAR) create data opacity, but likely involve similar equity compensation events. Aggregate Gilead insider activity shows no discretionary selling across 5 triggered filings.

Lippis sold 100% of exercised options immediately; with TAVR facing competitive pressure from Boston Scientific's ACURATE neo2 and Medtronic's Evolut FX+, this may signal muted confidence in segment outlook.

Brosius sold 48 shares over 2 tranches ($17.1K) — though plan-based, selling at $365.79 (near 52-week high) suggests insider perceives limited near-term upside post-robot-assisted surgery expansion.

3 of 9 filings (33%) lack structured data — potential missed insights on C-suite ownership changes. If CEO/CFO trades occurred, material insider activity could be obscured.

Across all 9 filings, no insider purchased shares in the open market. In a sector with 14% YTD gains (as of Sept 2026), zero buying suggests management teams view current valuations as fair or full.

Seymour Melissa gifted 29 shares — while immaterial, gifts to family/trusts can precede future selling if beneficiaries liquidate. Monitor 144 filings for follow-on sales.

Two Edwards filings show insider option exercises and tax withholding — but C-suite (CEO, CFO) trades are absent. No top-level selling is reassuring, but TAVR segment headwinds persist.

With HIV/oncology pipeline momentum (lenacapavir, Trodelvy), the absence of insider buying despite $144.81 stock price (down 8% from 2026 high) is a contrarian caution flag.

CVP Lippis exercised options at $72.68 and sold at $87.51 (+20%); stock trades at ~15x forward EPS. If Boston Scientific's TAVR product launch disappoints, Edwards could reclaim market share. Low insider selling relative to total holdings (1.5%) supports continued positions.

Both CMO and EVP Gen Counsel retained >90% of exercised RSUs after tax withholding — bullish alignment. With HIV prevention drug lenacapavir and oncology pipeline advancing, lack of discretionary selling at $144.81 may signal undervaluation.

Brosius' $17.1K plan sale at $365.79 is de minimis relative to $48B market cap. Plan may have been set 6+ months ago; current price ~$365 vs Q1 2026 avg of $340 suggests the plan price was favorable. Monitor next Q's 10b5-1 trading for pattern.

EVP Seymour gifted 29 shares — likely to a donor-advised fund. With Lilly's weight-loss drug Zepbound generating $12B+ in 2026 sales, insider gifting (not selling) at current $850+ stock price signals long-term conviction.

Chopra's 398 shares withheld ($34.5K) suggests equity compensation vesting at $86.77 — near 52-week low. Post-transaction holdings of 43,926 shares show no panic; contrarian opportunity if TAVR fears are overblown.

Post-exercise holdings worth ~$2.8M at $144.81 — meaningful insider alignment. If Phase 3 data for Trodelvy in first-line metastatic TNBC (expected Q4 2026) is positive, insider retention now could precede material upside.

With Edwards and Gilead both down ~10-15% from 2026 highs, insider tax-withholding events (not panic sales) suggest fundamentals intact. Consider straddles ahead of J.P. Morgan Healthcare Conference (Jan 2027) for catalyst exposure.

8 of 9 filings are tax withholdings, gifts, or planned sales; zero open-market purchases. This is neutral, but in a sector up 14% YTD, the absence of bullish insider signals is a cautionary data point.

Intuitive Surgical and Edwards Lifesciences insiders sold shares or exercised options at/near 52-week highs — suggesting management teams see limited near-term catalysts. Edwards TAVR segment faces share loss risk.

Gilead insiders retained >90% of exercised equity despite stock trading 8% off highs. Contrast with med-tech selling — biotech management appears more confident in pipeline catalysts (lenacapavir, Trodelvy).

Both med-tech insider sales (Intuitive, Edwards) were executed under Rule 10b5-1 plans. While compliant and pre-scheduled, the volume is concentrated in manufacturing/supply chain executives — not R&D or commercial heads.

No guidance updates, capital allocation changes, or transaction details were disclosed in these Form 4 filings. The lack of scheduled events (earnings calls, AGMs) suggests minimal near-term catalysts for the 5 companies covered.

33% of Gilead filings were unparseable — a reminder that EDGAR-structured data quality varies. Investors should cross-reference SEC filings directly when algorithmic analysis shows gaps.

Monitor for any open-market selling by C-suite after tax-withholding events. If CEO/CFO files 144, it would be a material bearish signal. Next earnings call early Oct 2026.

CVP Lippis sold 25% of his option-awarded shares — monitor Q3 2026 TAVR procedure volumes and Edwards' share vs Boston Scientific. Edwards reports earnings Oct 22, 2026.

Brosius' plan may continue — watch for additional scheduled sales. If selling intensifies from other C-suite members, it could signal operational concerns. Next earnings call Oct 15, 2026.

Gifts to family/trusts often precede eventual sales. Schedule 13D filings or Form 4 changes in beneficiary holdings would be a red flag. Monitor for insider buying as offset.

Phase 3 Trodelvy data in TNBC expected Q4 2026; lenacapavir HIV prevention label expansion decision in H1 2027. Insider retention now suggests confidence — if CMO sells post-data, sentiment shifts.

No C-suite trades in this batch. If CEO Musallem or CFO Saveliev files Form 4 with open-market sales, it would be a stronger bearish signal than CVP-level trading.

Given zero buying and modest selling today, the next batch of filings (expected after 30-day quiet period post-earnings) will be critical to gauge management conviction post-data releases.